Results 201 to 210 of about 111,871 (303)

244 PARP inhibitors

European Journal of Cancer Supplements, 2010
openaire   +1 more source

Targeting the Menin–KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation

European Journal of Haematology, EarlyView.
ABSTRACT Acute leukemias characterized by a shared epigenetic dependency on the menin–KMT2A axis rely on aberrant HOX‐driven transcriptional programs that sustain leukemic self‐renewal and impair differentiation. This dependency is most evident in KMT2A‐rearranged and NPM1‐mutated acute myeloid leukemia (AML), but also extends to other HOX‐dependent ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Mamdouh Skafi, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

GSK3β guides chromosomal repair pathway selection to support BRCA1-independent PARP inhibitor sensitivity. [PDF]

J Clin Invest
Leung JW, Gius D.
europepmc   +1 more source

Automodification of N‐terminal serine residues facilitates PARP2 release from DNA

The FEBS Journal, EarlyView.
PARP2 is involved in detecting DNA damage and its N‐terminal role is largely unknown. Based on biochemical and biophysical data, our findings suggest that in the presence of HPF1, N‐terminal serine 8 and 73 are enriched in auto‐ADP‐ribosylation. Our results provide insight into the mechanistic role of PARP2 N‐terminus in the PARylation‐dependent ...
Saurabh Singh Dhakar, Albert Galera‐Prat, Jin Cai, Julia Preisser, Tiila‐Riikka Kiema, Andreas Ladurner, Lari Lehtiö   +6 more
wiley   +1 more source

Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. [PDF]

Elife
Zhang Y, Xu M, Yuan J, Hu Z, Jiang J, Sun Y, Huang J, Wang Y, Wang B, Shen J, Long M, Fan Y, Montone KT, Tanyi J, Kim SH, Tavana O, Vonderheide RH, Chan HM, Domchek S, Zhang L, Hu X.   +20 more
europepmc   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

Genome-wide CRISPR-Cas9 screening identifies CLK1 inhibition as a strategy to restore PARP inhibitor sensitivity via ERCC1 isoform switching. [PDF]

Protein Cell
Liu C, Xu F, Wu Y, Li J, Ni M, Xia S, Chen L, Zhao H, Yu M, Zhou Y, Zhang M, Li J, Wu X, Huang Y, Zhu T, Chen X.   +15 more
europepmc   +1 more source

Steroidogenic compensation and lipid deficiency with enhanced NAD+ salvage in small‐for‐gestational‐age placenta

The FEBS Journal, EarlyView.
Fetal growth restriction is associated with placental metabolic adaptations. In small‐for‐gestational‐age placenta (SGA), cholesterol receptors and steroidogenic enzymes are upregulated, enhancing steroidogenesis. NAD salvage pathway is also increased to support NADP+/NADPH requirements.
Serena Xodo, Lorenza Driul, Vanessa Tolotto, Eros Di Giorgio, Luigi E. Xodo   +4 more
wiley   +1 more source

LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis. [PDF]

J Ovarian Res
Li X, Xiang Y, Gao J, Zong H, Li M, Gao R, Zhang H.   +6 more
europepmc   +1 more source

Real‐world prevalence of PD‐L1 positivity in early‐stage/metastatic triple‐negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study

Histopathology, EarlyView.
In the real‐world VANESSA study in triple‐negative breast cancer, PD‐L1‐positive prevalence was 38% in early‐stage and 20% in metastatic tumours, lower than in prospective trials. The lower prevalence in smaller versus larger tissue samples and by local versus central assessment underlines the importance of robust PD‐L1 testing to determine eligibility
Corrado D'Arrigo, Sitki Tuzlali, Romualdo Barroso‐Sousa, Nagi S El Saghir, Rebecca Dent, Nataša Medić‐Milijić, Gyungyub Gong, Shahin Sayed, Tu Thai Anh, Alisan Zirtiloglu, Götz Hartleben, Paula Toro, Iman Estaytieh, Enya Weber, Regula Deurloo, João Mouta, Lazar Popovic   +16 more
wiley   +1 more source